Switch View
© ACCESSWIRE
08.09.2025
ISIN: US59564R8079
Biodexa Pharmaceuticals plc
BDRX
LISTED
NASDAQ
Biodexa Moves Into Phase 3 With eRapa For FAP With First Patients Enrolled
News Preview
On Track To Be First Mover In $7Bn Addressable Market With No Current Therapeutic OptionsBy: Benzinga Staff Writer CARDIFF, UK / ACCESS Newswire / September 8, 2025 / Biodexa Pharmaceuticals PLC. (NASDAQ:BDRX), a late clinical-stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medic...
Themefolio
Profiler
Peergroup
© PR Newswire
08.09.2025
ISIN: JP3160400002
Eisai Co Ltd
45230
LISTED
XJPX
Eisai Presents Clinical Study Results of Novel Orexin Receptor Agonist E2086 for Narcolepsy at World Sleep 2025
News Preview
E2086 Showed Potential to Improve Wakefulness in People Living with Narcolepsy Type 1
TOKYO, Sept. 8, 2025 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the results from a Phase Ib clinical trial (NCT06462404) of its in-house developed novel selective orexin 2 receptor agonist E2086 have bee...
Themefolio
Profiler
Peergroup
© PR Newswire
08.09.2025
ISIN: KYG4818G1010
Innovent Biologics Inc
1801
LISTED
HKSE
Innovent Announces Phase 2 Results of Tigulixostat (IBI128, XOI) in Gout Patients were Published at the 27th Asia-Pacific League of Associations for Rheumatology Congress
News Preview
SAN FRANCISCO and SUZHOU, China, Sept. 7, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major disease areas, ann...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© PR Newswire
08.09.2025
ISIN: KR7145020004
Hugel, Inc.
145020
LISTED
KOE
Hugel strengthens Brazil presence with Letybo launch and new partner Derma Dream
News Preview
- The two companies hosted brand pre-launch events for toxin product Letybo in the first week of September to strengthen networks with local healthcare professionals
- The event marks a key milestone in Hugel's expansion across Latin America's aesthetic market
SEOUL, South Korea, Sept. 7, 2025 /PRNewswire/ -- Hugel Inc., a leading global medical...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© ACCESSWIRE
08.09.2025
ISIN: GB00BYX3WZ24
Hemogenyx Pharmaceuticals plc
HEMO
LISTED
LSE
Hemogenyx Pharmaceuticals PLC Announces Manufacturing Partnership with Made Scientific
News Preview
Hemogenyx Pharmaceuticals Announces Manufacturing Partnership with Made Scientific to Advance HG-CT-1 CAR-T Therapy CITY OF LONDON, GB / ACCESS Newswire / September 8, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), is pleased to announce a manufacturing partnership with Made Scientific, a leading U.S.-based cell therapy contract development and m...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.09.2025
ISIN: KYG4783B1032
Innocare Pharma Limited
9969
LISTED
HKSE
InnoCare Announces Approval of HIBRUKA (Orelabrutinib) for the Treatment of Marginal Zone Lymphoma in Singapore
News Preview
InnoCare's HIBRUKA (orelabrutinib) has been approved by the Health Sciences Authority (HSA) of Singapore for the treatment of adult patients with R/R MZL....
Themefolio
Profiler
Peergroup
© Globe Newswire
07.09.2025
ISIN: US2528281080
Dianthus Therapeutics Inc
DNTH
LISTED
NASDAQ
Dianthus Therapeutics to Host Conference Call and Webcast to Discuss Results from Phase 2 MaGic Trial of Claseprubart (DNTH103) in Generalized Myasthenia Gravis
News Preview
NEW YORK and WALTHAM, Mass., Sept. 07, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced a conference call and webcast to discuss results from the Phase 2 MaG...
Themefolio
Profiler
Peergroup
© PR Newswire
07.09.2025
ISIN: US4523271090
Illumina Inc
ILMN
LISTED
NASDAQ
Illumina® Protein Prep bringt neue Erkenntnisse aus der Proteomik für eine verbesserte Arzneimittelforschung und -entwicklung
News Preview
Illumina Protein Prep kann 9500 einzigartige menschliche Protein-Targets messen und bietet damit neue Einblicke in die Proteinbiologie, um die Entdeckung neuer Behandlungsmöglichkeiten für Krankheiten zu fördern
Nach dem Early-Access-Programm loben die Kunden die Skalierbarkeit, die hohe Konsistenz und den einfachen Einblick in den Workflow.
Die...
Themefolio
Profiler
Peergroup
© PR Newswire
07.09.2025
ISIN: US45166A1025
IDEAYA Biosciences Inc
IDYA
LISTED
NASDAQ
IDEAYA Biosciences and Hengrui Pharma Present Positive Phase 1 Data for IDE849 (SHR-4849), a Potential First-in-Class DLL3 TOP1 ADC, in Small Cell Lung Cancer at the IASLC 2025 World Conference on Lung Cancer
News Preview
80.0% (8/10) ORR and 70.0% (7/10) confirmed ORR in 2L SCLC; a 73.7% (14/19) ORR and 57.9% (11/19) confirmed ORR (1 pending confirmation) were observed across all lines of SCLC at the 2.4 mg/kg expansion dose of IDE84977.1% (27/35) ORR and 60.0% (21/35) confirmed ORR (4 pending confirmation) in 2L SCLC; a 73.2% (52/71) ORR and 47.9% (34/71) confir...
Themefolio
Profiler
Peergroup
© BusinessWire
07.09.2025
ISIN: US58933Y1055
Merck & Co Inc
MRK
LISTED
NYSE
Ifinatamab Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 Trial
News Preview
Results from the IDeate-Lung01 phase 2 trial showed that ifinatamab deruxtecan (I-DXd) demonstrated clinically meaningful response rates in patients with previously treated extensive-stage small cell lung cancer (ES-SCLC). These data were presented today during a late-breaking presentation (OA06.03) and included as part of the press program at the...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.09.2025
ISIN: CNE100003FF7
Shanghai Junshi Biosciences Co., Ltd.
1877
LISTED
HKSE
Junshi Biosciences Announces the Phase 3 Study of JS005 (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis Met Primary Endpoints
News Preview
JS005 has achieved positive results in a multi-center, randomized, double-blind, parallel, placebo-controlled pivotal registrational Phase 3 clinical study...
Themefolio
Profiler
Peergroup
© PR Newswire
07.09.2025
ISIN: KYG0146B1032
Akeso, Inc.
9926
LISTED
HKSE
Ivonescimab Plus Chemotherapy Demonstrates Consistent Global Benefit: HARMONi Data Update Shows OS HR=0.78, Nominal P=0.0332
News Preview
The overall survival (OS) hazard ratio (HR) in the HARMONi trial was 0.78, with a nominal p-value of 0.0332In the North American patients, the OS HR was 0.70The HARMONi trial has already demonstrated clinically meaningful and statistically significant progression-free survival (PFS) outcomesIn the HARMONi trial, clinical endpoint benefits, includ...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
07.09.2025
ISIN: US67080N1019
Nuvation Bio Inc
NUVB
LISTED
NYSE
Nuvation Bio Announces New Data from Pivotal Clinical Studies of IBTROZI™ (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at 2025 World Conference on Lung Cancer
News Preview
Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced new and updated results from the pivotal Phase 2 TRUST-I and TRUST-II studies evaluating IBTROZI™ (taletrectinib) for the treatment of adult patients with locally advanced or metastatic ROS1-positive (R...
Themefolio
Profiler
Peergroup
© PR Newswire
07.09.2025
ISIN: US6707031075
Nuvalent Inc
NUVL
LISTED
NASDAQ
Nuvalent Presents Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC at WCLC 2025
News Preview
Rolling NDA submission for zidesamtinib in TKI pre-treated advanced ROS1-positive NSCLC initiated under FDA's RTOR program, with completion on track for the third quarter of 2025
CAMBRIDGE, Mass., Sept. 7, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapie...
Themefolio
Profiler
Peergroup
© BusinessWire
07.09.2025
ISIN: US86627T1088
Summit Therapeutics Inc
SMMT
LISTED
NASDAQ
Longer-Term Follow-Up of Western Patients Showed Improving, Favorable Trend in Overall Survival in Global Phase III HARMONi Clinical Trial for Ivonescimab Plus Chemotherapy in 2L+ EGFRm NSCLC
News Preview
Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced data from the Phase III HARMONi trial featuring the novel, potential first-in-class investigational bispecific antibody, ivonescimab. The data was presented this morning as part of the Presidential Symposium at the International Association for the Study of...
Themefolio
Profiler
Peergroup
© PR Newswire
07.09.2025
ISIN: US4781601046
Johnson & Johnson
JNJ
LISTED
NYSE
Data published in The New England Journal of Medicine demonstrate RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) is re-setting survival expectations in first-line EGFR-mutated lung cancer
News Preview
Chemotherapy-free combination regimen ushers in new era for first-line treatment, with overall survival projected to exceed four years, surpassing monotherapy TKI osimertinib by more than one year
RARITAN, N.J., Sept. 7, 2025 /PR N...
Themefolio
Profiler
Peergroup
© PR Newswire
07.09.2025
ISIN: VGG111961055
Biohaven Ltd.
BHVN
LISTED
NYSE
BHVN Deadline: BHVN Investors Have Opportunity to Lead Biohaven Ltd. Securities Fraud Lawsuit
News Preview
NEW YORK, Sept. 6, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Biohaven Ltd. (NYSE: BHVN) between March 24, 2023 and May 14, 2025, both dates inclusive (the "Class Period"), of the important September 12, 2025 lead plaintiff deadline....
Themefolio
Profiler
Peergroup
© BusinessWire
06.09.2025
ISIN: US14070B3096
Capricor Therapeutics, Inc.
CAPR
LISTED
NASDAQ
CAPR Deadline: Rosen Law Firm Urges Capricor Therapeutics, Inc. (NASDAQ: CAPR) Stockholders with Losses to Contact the Firm for Information About Their Rights
News Preview
Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action lawsuit on behalf of purchasers of securities of Capricor Therapeutics, Inc. (NASDAQ: CAPR) between October 9, 2024 and July 10, 2025. Capricor is a clinical-stage biotechnology company.
For more information, submit a form, email attorney...
Themefolio
Profiler
Peergroup
© PR Newswire
06.09.2025
ISIN: US02155H2004
Altimmune Inc
ALT
LISTED
NASDAQ
ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit
News Preview
NEW YORK, Sept. 6, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Altimmune, Inc. (NASDAQ: ALT) between August 10, 2023 and June 25, 2025, both dates inclusive (the "Class Period"), of the important October 6, 2025 lead plaintiff deadline....
Themefolio
Profiler
Peergroup
© PR Newswire
06.09.2025
ISIN: US53216B1044
LifeMD, Inc.
LFMD
LISTED
NASDAQ
LFMD Investors Have Opportunity to Lead LifeMD, Inc. Securities Fraud Lawsuit First Filed by The Rosen Law Firm
News Preview
NEW YORK, Sept. 6, 2025 /PRNewswire/ --
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of LifeMD, Inc. (NASDAQ: LFMD) between May 7, 2025 and August 5, 2025, both dates inclusive (the "Cla...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.09.2025
ISIN: US10806X1028
BridgeBio Pharma, Inc.
BBIO
LISTED
NASDAQ
Encaleret Showed Parathyroid Hormone-Independent Normalization of Blood and Urine Calcium in Phase 2 Proof-of-Concept Study in Post-Surgical Hypoparathyroidism
News Preview
- 80% of post-surgical hypoparathyroidism participants achieved concomitant blood and 24-hour urine calcium in the normal reference range within 5 days of encaleret treatment initiation compared to 0% of participants on conventional therapy at baseline...
Themefolio
Profiler
Peergroup
© PR Newswire
06.09.2025
ISIN: US81684M1045
Semler Scientific Inc
SMLR
LISTED
NASDAQ
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Semler Scientific
News Preview
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Semler Scientific To Contact Him Directly To Discuss Their Options
If you purchased or acquired securities in Semler Scientific between March 10, 2021 and April 15, 2025 and would like to discuss your legal rights, call Faruqi &a...
Themefolio
Profiler
Peergroup
© PR Newswire
06.09.2025
ISIN: US67079U3068
Nutex Health Inc
NUTX
LISTED
NASDAQ
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Nutex Health
News Preview
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nutex To Contact Him Directly To Discuss Their Options
If you purchased or acquired securities in Nutex between August 8, 2024 and August 15, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh...
Themefolio
Profiler
Peergroup
© PR Newswire
06.09.2025
ISIN: US09061G1013
BioMarin Pharmaceutical Inc
BMRN
LISTED
NASDAQ
BioMarin Announces Positive Pivotal Phase 3 Data for PALYNZIQ® (pegvaliase-pqpz) in Adolescents with Phenylketonuria at 15th International Congress of Inborn Errors of Metabolism
News Preview
New data from Phase 3 PEGASUS study demonstrates a 49.7% decrease in mean blood Phe levels in adolescents aged 12-17 treated with PALYNZIQ
BioMarin's planned submission to global health authorities on track for second half of 2025
SAN RAFAEL, Calif., Sept. 6, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced new dat...
Themefolio
Profiler
Peergroup
© PR Newswire
06.09.2025
ISIN: US76029N1063
Replimune Group Inc
REPL
LISTED
NASDAQ
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune
News Preview
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Replimune To Contact Him Directly To Discuss Their Options
If you purchased or acquired securities in Replimune between November 22, 2024 and July 21, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi par...
Themefolio
Profiler
Peergroup
© PR Newswire
06.09.2025
ISIN: VGG111961055
Biohaven Ltd.
BHVN
LISTED
NYSE
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biohaven
News Preview
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Biohaven To Contact Him Directly To Discuss Their Options
If you purchased or acquired securities in Biohaven between March 24, 2023 and May 14, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner J...
Themefolio
Profiler
Peergroup
© PR Newswire
06.09.2025
ISIN: US15135B1017
Centene Corp
CNC
LISTED
NYSE
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Centene
News Preview
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Centene To Contact Him Directly To Discuss Their Options
If you purchased or acquired securities in Centene between December 12, 2024 and June 30, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Themefolio
Profiler
Peergroup
© PR Newswire
06.09.2025
ISIN: US90466Y1038
Unicycive Therapeutics, Inc.
UNCY
LISTED
NASDAQ
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Unicycive Therapeutics
News Preview
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Unicycive To Contact Him Directly To Discuss Their Options
If you purchased or acquired securities in Unicycive between March 29, 2024 and June 27, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partne...
Themefolio
Profiler
Peergroup
© PR Newswire
06.09.2025
ISIN: US02157Q1094
Alto Neuroscience, Inc.
ANRO
LISTED
NYSE
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto Neuroscience
News Preview
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Alto To Contact Him Directly To Discuss Their Options
If you purchased or otherwise acquired stock of Alto (a) Alto common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Co...
Themefolio
Profiler
Peergroup
© PR Newswire
06.09.2025
ISIN: US53216B1044
LifeMD, Inc.
LFMD
LISTED
NASDAQ
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of LifeMD
News Preview
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In LifeMD To Contact Him Directly To Discuss Their Options
If you ourchased or acquired securities in LifeMD between May 7, 2025 and August 5, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh W...
Themefolio
Profiler
Peergroup
© PR Newswire
06.09.2025
ISIN: US78349D1072
Rxsight Inc
RXST
LISTED
NASDAQ
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RxSight
News Preview
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In RxSight To Contact Him Directly To Discuss Their Options
If you purchased or acquired securities in RxSight between November 7, 2024 and July 8, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner J...
Themefolio
Profiler
Peergroup
© PR Newswire
06.09.2025
ISIN: US14070B1017
Capricor Therapeutics, Inc.
CAPR
LISTED
NASDAQ
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor Therapeutics
News Preview
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Capricor To Contact Him Directly To Discuss Their Options
If you purchased or acquired securities in Capricor between October 9, 2024 and July 10, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Themefolio
Profiler
Peergroup
© PR Newswire
06.09.2025
ISIN: US02155H2004
Altimmune Inc
ALT
LISTED
NASDAQ
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune
News Preview
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Altimmune To Contact Him Directly To Discuss Their Options
If you purchased or acquired securities in Altimmune between August 10, 2023 and June 25, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partn...
Themefolio
Profiler
Peergroup
© PR Newswire
06.09.2025
ISIN: US4781601046
Johnson & Johnson
JNJ
LISTED
NYSE
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) prevents acquired resistance versus osimertinib in first-line EGFR-mutated non-small cell lung cancer
News Preview
RYBREVANT® combination extends survival and significantly reduces common EGFR and MET resistance mutations seen with osimertinib-based treatment
BARCELONA, Spain, Sept. 6, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced new analyses from the Phase 3 MARIPOSA study showing that first-line treatment with RYBREVANT® (amivantama...
Themefolio
Profiler
Peergroup
© EQS Newswire
06.09.2025
ISIN: CA68237C1059
Onco-Innovations Limited
ONCO
LISTED
CSE
Dr. John Mackey wird Mitglied im “Scientific and Clinical Advisory Board” von Onco-Innovations
News Preview
EQS-Media / 06.09.2025 / 08:45 CET/CEST
Onco-Innovations Ltd. (ISIN: CA68237C1059 / WKN: A3EKSZ), Onco oder das Unternehmen, freut sich, die Ernennung von Dr. John Mackey, einem emeritierten Professor am Lehrstuhl für Onkologie der University of Alberta, in sein Scientific and Clinical Advisory Board bekannt zu geben. Mit seinen Fachkenntnisse......
Themefolio
Profiler
Peergroup
© PR Newswire
06.09.2025
ISIN: US90466Y1038
Unicycive Therapeutics, Inc.
UNCY
LISTED
NASDAQ
UNCY Investors: If you Lost Significant Money in UNCY Contact Robbins LLP for Information About the Securities Fraud Class Action Against Unicycive Therapeutics, Inc.
News Preview
SAN DIEGO, Sept. 5, 2025 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Unicycive Therapeutics, Inc. (NASDAQ: UNCY) securities between March 29, 2024 and June 27, 2025. Unicycive is a clinical-stage biotechnology company that identifies, develops, and comme...
Themefolio
Profiler
Peergroup
© PR Newswire
06.09.2025
ISIN: US6404911066
Neogen Corp
NEOG
LISTED
NASDAQ
NEOGEN SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against Neogen Corporation - NEOG
News Preview
NEW ORLEANS, Sept. 5, 2025 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until September 16, 2025 to file lead plaintiff applications in a securities class action lawsuit against Neogen Corporation (NasdaqGS: NEOG), if they purchased the Company's shares between January 5, 2023 through June...
Themefolio
Profiler
Peergroup
© BusinessWire
06.09.2025
ISIN: US8740602052
Takeda Pharmaceutical Company
TAK
LISTED
NYSE
U.S. FDA Approves Expanded Indication for VONVENDI® [von Willebrand factor (Recombinant)] for Adults and Children with Von Willebrand Disease
News Preview
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for VONVENDI® [von Willebrand factor (Recombinant)], expanding the indication to include routine prophylaxis to reduce the frequency of bleeding episodes in adults with von Willebrand Diseas...
Themefolio
Profiler
Peergroup
© PR Newswire
06.09.2025
ISIN: US2358511028
Danaher Corp
DHR
LISTED
NYSE
DHR Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Danaher Corporation - DHR
News Preview
NEW YORK, Sept. 5, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential breaches of fiduciary duties by the directors and officers of Danaher Corporation (NYSE: DHR).
If you cur...
Themefolio
Profiler
Peergroup
© PR Newswire
06.09.2025
ISIN: AU000000TLX2
Telix Pharmaceuticals Ltd
TLX
LISTED
ASX
Rosen Law Firm Encourages Telix Pharmaceuticals Ltd. Investors to Inquire About Securities Class Action Investigation - TLX
News Preview
NEW YORK, Sept. 5, 2025 /PRNewswire/ --
Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) resulting fr...
Themefolio
Profiler
Peergroup
© PR Newswire
06.09.2025
ISIN: US76029N1063
Replimune Group Inc
REPL
LISTED
NASDAQ
REPL Deadline: REPL Investors with Losses in Excess of $100K Have Opportunity to Lead Replimune Group, Inc. Securities Lawsuit First Filed by The Rosen Law Firm
News Preview
NEW YORK, Sept. 5, 2025 /PRNewswire/ --
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Replimune Group, Inc. (NASDAQ: REPL) between November 22, 2024 and July 21, 2025, both dates inclus...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.09.2025
ISIN: CA17104U1021
Christina Lake Cannabis Corp
CLC
LISTED
CSE
Christina Lake Cannabis Announces Debenture Extension
News Preview
VANCOUVER, British Columbia, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Christina Lake Cannabis Corp. (the “Company” or “CLC” or “Christina Lake Cannabis”) (CSE: CLC) (OTCQB: CLCFF) (FRANKFURT: CLB) announces that further to the press release dated August 22, 2025, the holders (the "Holders") of convertible debentures in the principal amount of $710,000...
Themefolio
Profiler
Peergroup
© PR Newswire
06.09.2025
ISIN: US78349D1072
Rxsight Inc
RXST
LISTED
NASDAQ
RXST Investors Have Opportunity to Lead RxSight, Inc. Securities Fraud Lawsuit
News Preview
NEW YORK, Sept. 5, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of RxSight, Inc. (NASDAQ: RXST) between November 7, 2024 and July 8, 2025, both dates inclusive (the "Class Period"), of the important September 22, 2025 lead plaintiff deadline....
Themefolio
Profiler
Peergroup
© Globe Newswire
05.09.2025
ISIN: CA7615161030
Revive Therapeutics Ltd.
RVV
LISTED
CSE
Revive Therapeutics Announces Extension of Proposed Private Placement
News Preview
TORONTO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to developing innovative therapeutics for critical medical needs, announces that it is extending is previously announced private placement offering of up to 30,952...
Themefolio
Profiler
Peergroup
© PR Newswire
05.09.2025
ISIN: CA09076M1014
BioVaxys Technology Corp.
BIOV
LISTED
CSE
BIOVAXYS ANNOUNCES SHARE CONSOLIDATION
News Preview
VANCOUVER, BC, Sept. 5, 2025 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") announces, further to its news release dated August 27, 2025, the consolidation of its common shares ("Common Shares") on the basis of ten (10) pre-consolidation Common Shares for one (1) post-consolidation Common Sh...
Themefolio
Profiler
Peergroup
© PR Newswire
05.09.2025
ISIN: CA09076M1014
BioVaxys Technology Corp.
BIOV
LISTED
CSE
BIOVAXYS ANNOUNCES SHARE CONSOLIDATION
News Preview
VANCOUVER, BC, Sept. 5, 2025 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") announces, further to its news release dated August 27, 2025, the consolidation of its common shares ("Common Shares") on the basis of ten (10) pre-consolidation Common Shares for one (1) post-consolidation Co...
Themefolio
Profiler
Peergroup
© Newsfile
05.09.2025
ISIN: CA74141E1043
PreveCeutical Medical Inc.
PREV
LISTED
CSE
PreveCeutical Closes Initial Tranche of Non-Brokered Private Placement
News Preview
Vancouver, British Columbia--(Newsfile Corp. - September 5, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that, further to its news release dated August 5, 2025, it has closed an initial tranche (the "Initial Tranche") of its previously announced $1,000,...
Themefolio
Profiler
Peergroup
© PR Newswire
05.09.2025
ISIN: US2289031005
Artivion Inc
AORT
LISTED
NYSE
Artivion to Participate in Morgan Stanley 23rd Annual Global Healthcare Conference
News Preview
ATLANTA, Sept. 5, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate at the upcoming Morgan Stanley 23rd Annual Global Healthcare Conference on Wednesday, September 10, 2025, at the Sheraton New York Times Square Hotel. The Company's...
Themefolio
Profiler
Peergroup
© BusinessWire
05.09.2025
ISIN: US64135M1053
Neurogene Inc
NGNE
LISTED
NASDAQ
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 47,040 shares of...
Themefolio
Profiler
Peergroup
© BusinessWire
05.09.2025
ISIN: US24661P8077
Delcath Systems, Inc.
DCTH
LISTED
NASDAQ
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company’s Compensation Committee, as material inducements to three individuals whose employment c...
Themefolio
Profiler
Peergroup
© PR Newswire
05.09.2025
ISIN: US8342033094
Soleno Therapeutics Inc
SLNO
LISTED
NASDAQ
Rosen Law Firm Encourages Soleno Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - SLNO
News Preview
NEW YORK, Sept. 5, 2025 /PRNewswire/ --
Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Soleno Therapeutics, Inc. (NASDAQ: SLNO) resulti...
Themefolio
Profiler
Peergroup
© PR Newswire
05.09.2025
ISIN: US67079U3068
Nutex Health Inc
NUTX
LISTED
NASDAQ
NUTX Investors Have Opportunity to Lead Nutex Health Inc. Securities Fraud Lawsuit
News Preview
NEW YORK, Sept. 5, 2025 /PRNewswire/ --
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nutex Health Inc. (NASDAQ: NUTX) between August 8, 2024 and August 14, 2025, both dates inclusive (...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.09.2025
ISIN: FR0010417345
Dbv Technologies SA
DBV
LISTED
EURONEXT
DBV Technologies Establishes an At-The-Market (ATM) Program on Nasdaq
News Preview
Châtillon, France, September 5, 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.09.2025
ISIN: BE0974358906
Nyxoah S.A.
NYXH
LISTED
NASDAQ
Publication relating to transparency notifications
News Preview
...
Themefolio
Profiler
Peergroup
© BusinessWire
05.09.2025
ISIN: US1241551027
Butterfly Network Inc
BFLY
LISTED
NYSE
Rutgers Robert Wood Johnson Medical School Study Published in JAMA Confirms Butterfly-Enabled POCUS Program Heavily Focused on LUNG US with AI Assistance Reduces Stay and Cost
News Preview
Butterfly Network, Inc. (NYSE: BFLY), a digital health company transforming care through portable, semiconductor-based ultrasound technology and intuitive software, today announced that the full results of the POCUS for Cardiopulmonary Assessment and Resource Evaluation (POCUS-CARE) trial have been published in The Journal of the American Medical...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.09.2025
ISIN: US4037831033
Gyre Therapeutics Inc
CBIO
LISTED
NASDAQ
Gyre Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
News Preview
Gyre Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.09.2025
ISIN: US75383L1026
Rapport Therapeutics Inc.
RAPP
LISTED
NASDAQ
Rapport Therapeutics to Announce Topline Results for RAP-219 Phase 2a Trial in Focal Onset Seizures on Monday, September 8, 2025
News Preview
BOSTON and SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced that it will host a confer...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.09.2025
ISIN: US68622P1093
Oric Pharmaceuticals Inc
ORIC
LISTED
NASDAQ
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
News Preview
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on September 2, 2025 (the “Grant Date”), ORIC granted a total of 292,500 non-qualified st...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.09.2025
ISIN: US2825591033
89Bio, Inc.
ETNB
LISTED
NASDAQ
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
SAN FRANCISCO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company’s Board...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.09.2025
ISIN: US04301G1022
Artelo Biosciences, Inc.
ARTL
LISTED
NASDAQ
Artelo Biosciences Announces Closing of $3.0 Million Public Offering
News Preview
SOLANA BEACH, Calif., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced the closing of its previously announced underw...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
